MEG3 and breast cancer: Furthermore, 5‐Aza‐dC treatment decreased viability of BC cells less significantly than combined treatments of 5‐Aza‐dC and pcDNA3.1‐MEG3 (P < .05), and si‐MEG3 could counteract the effects of 5‐Aza‐dC on viability of BC cells (P < .05) (Figure 3B).